Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial-Reference-Cited by-同舟云学术

Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial

Published:2019-11 Issue:3 Volume:1 Page:e145-e153
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Verhoef Lise M,den Broeder Nathan,Thurlings Rogier M,van der Laan Willemijn H,van der Weele Wilfred,Kok Marc R,Bernelot Moens Hein J,Woodworth Thasia G,van den Bemt Bart J F,van den Hoogen Frank H J,den Broeder Alfons A

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference31 articles.

1. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis;van der Woude;Best Pract Res Clin Rheumatol,2018

2. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Care Res,2016

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

4. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update;Stoffer;Ann Rheum Dis,2016

5. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity;Verhoef;Cochrane Database Syst Rev,2019

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Montelukast as a Rescue and Premedication for Rituximab Infusion Reactions;The Journal of Rheumatology;2024-06-15

2. Comparison of rituximab efficacy in treatment-naïve and refractory inflammatory myopathies: experiences from a tertiary care centre;Rheumatology;2024-05-30

3. Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis;Musculoskeletal Care;2024-05

4. Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial;RMD Open;2024-04

5. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder;Journal of Neuroimmunology;2024-02